Uncategorized
This week in Drug Discovery (20 – 24 April)
News round-up for 20 – 24 April by Bruno Quinney, Content Team at DDW.
This week, an obesity drug could improve liver health independent of weight loss. Elsewhere, Lilly is back in the news for both its type 2 diabetes drug and the company’s latest acquisition.
The top stories:
GLP-1 improves liver health independent of weight loss
Researchers at Sinai Health have found that semaglutide acts directly on a subset of liver cells to improve organ function and does so independently of weight loss.
Digital lung ‘twins’ could predict drug efficacy in humans
Healthcare company Ebenbuild has developed lung digital twin technology, which uses patient-specific models to predict drug deposition.
MHRA grants trial authorisation to CRS therapy
The TOPICAL trial will investigate Poolbeg Pharma’s therapy, POLB 001, in approximately 30 relapsed/refractory multiple myeloma patients receiving the approved bispecific antibody teclistamab.
Lilly publishes data confirming Foundayo’s safety profile
Eli Lilly has shared positive topline results from the Phase III ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron), compared to insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk.
Read more…
Antibody-drug conjugate company CrossBridge Bio acquired by Lilly
Eli Lilly has signed a definitive agreement to acquire preclinical biotechnology company CrossBridge Bio for up to $300 million in cash, inclusive of an upfront payment and a subsequent milestone-dependent payment.
The post This week in Drug Discovery (20 – 24 April) appeared first on Drug Discovery World (DDW).